SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio's new 3-year clinical roadmap detailing ANKTIVA's expansion across numerous cancer types, sepsis, and lymphopenia, alongside impressive revenue growth, is fueling robust community discussion and short squeeze speculation, as the company is seen transforming beyond a single-drug focus.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending as its enhanced offer for Warner Bros. Discovery, including financial protections and a ticking fee, has prompted WBD to re-engage in deal discussions. The community is actively debating PSKY's perceived clearer regulatory path compared to Netflix's ongoing antitrust scrutiny, while also weighing the potential debt implications for PSKY if the acquisition proceeds.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending sharply lower as fears escalate that Anthropic's Claude AI tool could disrupt its legacy COBOL modernization services, despite community discussions highlighting IBM's established AI integrations and robust fundamentals.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx (ARDX) is trending amid debate following mixed Q4 results, where robust Ibsrela revenue growth and extended patent life are weighed against increased operating expenses that temper near-term profitability expectations. The community is split between those viewing the stock as deeply undervalued with strong long-term potential and ongoing buyout speculation, and those cautious about immediate financial performance and market volatility.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian ($TEAM) is trending amid a dramatic stock decline, even after reporting solid financials, as investor panic over the "AI disruption" narrative weighs heavily on the broader SaaS sector; community discussion is sharply divided between fears of impending bankruptcy and strong conviction that the stock is "criminally oversold."

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

ZETA is actively debated amid a deep sector-wide software sell-off, fueled by "AI replacement" fears, causing many investors to view current price drops as an opportune "discount" to accumulate shares before its anticipated strong earnings report.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

Vir Biotechnology is trending due to a global strategic collaboration with Astellas for its prostate cancer T-cell engager, VIR-5500, backed by promising updated Phase 1 data. The community is actively discussing the potential for a significant run, with some anticipating a short squeeze, while others remain cautious, expecting a historical pullback.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as market participants react to the Supreme Court's recent tariff ruling and former President Trump's subsequent plans for new trade policies. Community dialogue centers on the political implications for the stock and broader economic uncertainty, overshadowing traditional company fundamentals.

Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.

Protara Therapeutics Inc

Protara Therapeutics is trending amid community discussions surrounding its interim Phase 2 data for bladder cancer treatment TARA-002, which demonstrated strong 6-month complete response rates. A recently priced public offering and upcoming investor conference presentations are also contributing to significant price volatility and debate over the stock's current valuation and future potential.

BlackRock Institutional Trust Company N.A. - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF ($IGV) is trending as widespread fears of AI disruption, particularly from Anthropic's Claude and recent research, are driving a dramatic "SaaS-pocalypse" sell-off across the software sector, though many argue the market's reaction is an extreme overreaction and a significant buying opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Myomo, Inc. (MYO) Reports Q3 Loss, Tops Revenue Estimates

Myomo (MYO) delivered earnings and revenue surprises of +18.18% and +8.74%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Prestige Consumer Healthcare (PBH) Beats Q2 Earnings and Revenue Estimates

Prestige Consumer Healthcare (PBH) delivered earnings and revenue surprises of +10.31% and +6.87%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of Myomo plunged 42% in after-hours trading Monday after the maker of wearable medical robotics cut its 2025 revenue forecast and reported a bigger-than-expected loss in the second quarter (Q2).The company now sees full-year revenue of $40 million to $42 million, compared with prior guidance of $50 million to $53 million, and attributed the downward revision to lower-than-expected operating trends. It also sees third-quarter revenue of $9.5 million to $10 million.Revenue for the three months ended June 30 rose 28% from a year earlier to $9.7 million, above the Koyfin analyst estimate of $9.15 million. However, the company’s losses widened.&nbsp;Adjusted EBITDA loss was $4 million, missing analysts’ expectations of a $3.82 million loss. The company reported a net loss of $4.6 million, compared with expectations for a loss of $4.33 million in EBIT.&nbsp;Earnings per share were a loss of $0.11 per share, in line with estimates, on a GAAP basis.More than half of Q2 revenue came from Medicare Part B patients, helped by higher unit volumes and average selling prices.&nbsp;However, key forward indicators weakened: orders and insurance authorizations slipped 3% to 207 units, backlog fell 18% to 230 units, and gross margin narrowed to 62.7% from 70.8% due to higher material and overhead costs.CEO Paul R. Gudonis said performance was impacted by lower-quality leads resulting from changes to digital advertising, weaker conversion rates to pipeline additions and orders, and a cycle time issue where 40% to 50% of quarterly pipeline additions originate from leads generated more than a year prior.&nbsp;He noted that patient response, clinical profiles, and a stronger focus on outcomes were leading to more candidates being ruled ineligible for the MyoPro device.&nbsp;Much of the company’s 2025 advertising spend, he added, is expected to yield new patients in 2026 and beyond; however, recent actions and sustained ad spending are also expected to help improve operating metrics sooner.Operating expenses surged 65% to $10.6 million, driven by higher payroll, engineering costs, and a 162% increase in advertising outlays.&nbsp;Cash used in operations increased to $8.9 million from $1.9 million a year earlier, with non-recurring outflows, including $2.9 million in incentive payments and delayed insurance reimbursements, contributing to the shortfall.To curb costs, Myomo reduced its workforce by 8% in July and is scaling back spending on outside services, targeting at least $2 million in annual cash savings. The company ended the quarter with $15.5 million in cash, cash equivalents, and short-term investments, bolstered by $4 million in new borrowings.On Stocktwits, retail sentiment for Myomo was ‘extremely bullish’ early Tuesday amid a 4,700% surge in 24-hour message volume.<a href="https://stocktwits.com/symbol/MYO">Myomo’s stock</a> has declined by 72.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Myomo logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Medical Device Maker Myomo’s Stock Crashed 42% In After-Hours Trading

The wearable medical robotics maker slashed its 2025 revenue forecast and posted a wider-than-expected quarterly loss due to weaker lead quality, slower conversions, and rising costs.

Equity

Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates

Myomo (MYO) delivered earnings and revenue surprises of 0.00% and +6.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Capricor (CAPR) Moves 20.4% Higher: Will This Strength Last?

Capricor (CAPR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Myomo, Inc. is a wearable medical robotics company, which engages in the business of developing, designing, and producing myoelectric orthotics for people with neuromuscular disorders. The firm is also involved in selling products through various other sales channels including through orthotics and prosthetics providers, veterans’ administration, and to distributors in certain accounts and geographic markets. The company was founded by Stephen Kelly, John McBean, Mira Sahney, and Kailas N. Narendran on September 1, 2004 and is headquartered in Burlington, MA.

Current Price	$0.691
Prev Close	$0.7319
Open	$0.7395
Dividend Yield	0.00%
50-Day Moving Average	$0.9222
Beta	1.56
Avg. Volume	600,833.10
PE Ratio	-2.54

52-Week High	$6.30
52-Week Low	$0.711
Market Capitalization	$28.13M
EPS (Annual)	-$0.1638
Price to Book	1.92
Revenue Per Employee	$175,952.43

MYO
Myomo Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MYO News

MYOMyomo Inc